Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
TEST:
RaDaR™ assay
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
NeoGenomics
Type:
CE Marked
Related tests:
‹
InVisionFirst®-Lung (1)
Early-stage NSCLC Panel
InVisionSeq™
KRAS Gene Sequencing, KRAS Exons 2-4 (includes G12C mutation) Test
Myeloid Molecular Profile
Neo Comprehensive - Myeloid Disorders Assay
Neo Comprehensive - Solid Tumor Assay
Neo Comprehensive™ - Heme Cancers
NeoLAB® Solid Tumor Liquid Biopsy
NeoTYPE® Lung Tumor Profile
NexCourse®
InVisionFirst®-Lung (1)
Early-stage NSCLC Panel
InVisionSeq™
KRAS Gene Sequencing, KRAS Exons 2-4 (includes G12C mutation) Test
Myeloid Molecular Profile
Neo Comprehensive - Myeloid Disorders Assay
Neo Comprehensive - Solid Tumor Assay
Neo Comprehensive™ - Heme Cancers
NeoLAB® Solid Tumor Liquid Biopsy
NeoTYPE® Lung Tumor Profile
NexCourse®
›
Details
Evidence
News
Search handles
@teamoncology
Search handles
@teamoncology
Filter by
Latest
10ms
#ASCO23 #BreastCancer #OncoAlert Take Home Message 2 Biomarker PENELOPE-B: RCT subanalysis using RaDaR in postoperative PAL. Poor prognosis when ctDNA becomes positive. Low sensitivity for late recurrence. SOFT trial: PAM50 as a prognostic factor, not a predictive factor in… https://t.co/CAaWtnRvWn (@teamoncology)
10 months ago
Circulating tumor DNA
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • RaDaR™ assay
10ms
#ASCO23 #BreastCancer #OncoAlert Take Home Message 2 Biomarker PENELOPE-B: RCT subanalysis using RaDaR in postoperative PAL. Poor prognosis when ctDNA becomes positive. Low sensitivity for late recurrence. SOFT trial: PAM50 as a prognostic factor, not a predictive factor in… https://t.co/SwA9afc0c9 (@teamoncology)
10 months ago
Circulating tumor DNA
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • RaDaR™ assay
over1year
Tumor informed highly sensitive ctDNA assay (RaDaR) in TN early stage BC (TN-TRACK study) detects clinical relapse with a longer lead time than dPCR (6 m vs 3 m). We need this kind of data also for luminal disease. #SABCS22 ()
over 1 year ago
Clinical • Circulating tumor DNA
|
RaDaR™ assay
almost2years
CHiRP real-world (N=83 w/ ctDNA): ctDNA MRD and late recurr in high-risk HR+/HER2- #bcsm -WES RaDaR assay -6 pts distant recurr: all detected by ctDNA but only 2 w/ 1. sample (& 1 local recurr missed) -2 ctDNA+ pts: not recurred -Med lead time ~12 mon @OncoAlert #ASCO22 ()
almost 2 years ago
Real-world evidence • Clinical • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
RaDaR™ assay
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login